PDF(Pubmed)
Abstract：
Leading anti-tumour therapeutic strategies typically involve surgery and radiotherapy for locally advanced (non-metastatic) cancers, while hormone therapy, chemotherapy, and molecular targeted therapy are the current treatment options for metastatic cancer. Despite the initially high sensitivity rate to anticancer therapies, a large number of patients develop resistance, leading to a poor prognosis. The mechanisms related to drug resistance are highly complex, and long non-coding RNAs appear to play a crucial role in these processes. Among these, the lncRNA homeobox transcript antisense intergenic RNA (HOTAIR), widely implicated in cancer initiation and progression, likewise plays a significant role in anticancer drug resistance. It can modulate cell activities such as proliferation, apoptosis, hypoxia, autophagy, as well as epithelial-mesenchymal transition, thereby contributing to the development of resistant tumour cells. In this manuscript, we describe different mechanisms of antitumor drug resistance in which HOTAIR is involved and suggest its potential as a therapeutic predictive biomarker for the management of cancer patients.
摘要：
领先的抗肿瘤治疗策略通常涉及局部晚期（非转移性）癌症的手术和放疗。而激素治疗,化疗,和分子靶向治疗是目前转移性癌症的治疗选择。尽管最初对抗癌疗法的敏感性很高，大量患者产生耐药性，导致预后不良。耐药机制非常复杂,长链非编码RNA似乎在这些过程中起着至关重要的作用。其中,lncRNA同源盒转录本反义基因间RNA(HOTAIR)，与癌症的发生和进展密切相关，同样在抗癌药物耐药中起着重要作用。它可以调节细胞活动，如增殖，凋亡，缺氧,自噬,以及上皮-间质转化，从而促进耐药肿瘤细胞的发展。在这份手稿中,我们描述了HOTAIR参与的抗肿瘤药物耐药的不同机制,并提出了HOTAIR作为癌症患者治疗预测生物标志物的潜力.
